The deal positions MilliporeSigma at the center of commercial manufacturing for three breakthrough gene therapies targeting sickle cell disease, ?-thalassemia, and cerebral adrenoleukodystrophy
The initiative aims to encourage women and parents to seek timely medical guidance on cervical cancer prevention and HPV awareness
Growth was supported by stronger COVID vaccine sales and expanded government supply agreements in international markets
The deal the group says marks a decisive push deeper into severe infectious diseases and the build-out of a global specialty pharmaceuticals platform
The start of our Phase 3 trial for an H5 influenza vaccine marks a significant milestone
The approval, following a positive recommendation from the European Medicines Agency’s CHMP, makes the vaccine valid across all 27 EU member states
Marking three years of the National Diagnostics Catapult (NDxC), the conclave launched the Impact Report and unveiled environmental surveillance kits
The Clinical Trial Application (CTA) approval clears the way for the company to launch trial locations in France and Romania
ENFLONSIA is a long-acting monoclonal antibody designed to shield infants through a typical five-month RSV season with a single, fixed dose
The event marks a significant push into South Korea’s rapidly expanding bio-health ecosystem
Subscribe To Our Newsletter & Stay Updated
